Next Article in Journal
Evaluating the Potential of Younger Cases and Older Controls Cohorts to Improve Discovery Power in Genome-Wide Association Studies of Late-Onset Diseases
Previous Article in Journal
Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients
Previous Article in Special Issue
Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer
Open AccessReview

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma

by Matthew Loft 1,2,*, Belinda Lee 1,2, Jeanne Tie 1,2,3,4 and Peter Gibbs 1,2,3
1
Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, Australia
2
Department of Medical Biology, The University of Melbourne, Parkville 3010, Australia
3
Department of Medical Oncology, Western Health, Footscray 3011, Australia
4
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2019, 9(3), 37; https://doi.org/10.3390/jpm9030037
Received: 28 May 2019 / Revised: 3 July 2019 / Accepted: 16 July 2019 / Published: 18 July 2019
(This article belongs to the Special Issue Biomarkers and Personalized Therapies in Pancreatic Cancer)
Pancreatic adenocarcinoma remains one of the most aggressive cancers with an ongoing dismal survival rate despite some recent advances in treatment options. This is largely due to the typically late presentation and limited effective therapeutic options in advanced disease. There are numerous circulating biomarkers that have potential clinical application as tumour markers, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), exosomes and circulating tumour proteins. This review will focus on the development of ctDNA as a non-invasive liquid biopsy, with its high sensitivity and specificity having potential clinical applications in pancreatic cancer. These include a role in screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and for patients with advanced disease; tumour genotyping and monitoring treatment response. Prospective randomised adjuvant clinical trials are currently underway, exploring the impact of ctDNA-guided adjuvant therapy decisions. In this review, we provide perspectives on the current literature and considerations of future directions. View Full-Text
Keywords: pancreatic cancer; circulating tumour DNA (ctDNA), biomarkers; liquid biopsy; personalised oncology; targeted therapy; intratumoural heterogeneity; molecular resistance pancreatic cancer; circulating tumour DNA (ctDNA), biomarkers; liquid biopsy; personalised oncology; targeted therapy; intratumoural heterogeneity; molecular resistance
MDPI and ACS Style

Loft, M.; Lee, B.; Tie, J.; Gibbs, P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. J. Pers. Med. 2019, 9, 37.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop